

1 **Retrospective screening for SARS-CoV-2 among 5,800 hospitalizations related to influenza-like**  
2 **illness during the 2018-19 pre-pandemic and 2019-2020 pandemic influenza seasons in the**  
3 **VAHNSI network, Spain.**

4

5 Ainara Mira-Iglesias<sup>1\*</sup>, Beatriz Mengual-Chuliá<sup>1\*</sup>, Laura Cano<sup>1</sup>, Javier García-Rubio<sup>1</sup>,  
6 Miguel Tortajada-Girbés<sup>3</sup>, Mario Carballido-Fernández<sup>4,5</sup>, Juan Mollar-Maseres<sup>6</sup>,  
7 Germán Schwarz-Chavarri<sup>7</sup>, Sandra García-Esteban<sup>1</sup>, Joan Puig-Barberà, Javier Díez-Domingo<sup>1&</sup>,  
8 F. Xavier López-Labrador<sup>1,2,&,#</sup>, for the Valencia Hospital Network for the Study of Influenza and  
9 Respiratory Viruses Disease<sup>1</sup>

10

11 1. Fundación para el Fomento de la Investigación Sanitaria y Biomédica de la Comunitat  
12 Valenciana (FISABIO-Public Health), Valencia, Spain

13 2. Consorcio de Investigación Biomédica de Epidemiología y Salud Pública (CIBERESP), Instituto  
14 de Salud Carlos III, Madrid, Spain

15 3. Hospital Doctor Peset, Valencia, Spain

16 4. Hospital General Universitario de Castellón, Castellón, Spain

17 5. Universidad CEU Cardenal Herrera, Castellón, Spain

18 6. Hospital Universitario y Politécnico La Fe, Valencia, Spain

19 7. Hospital General de Alicante, Alicante, Spain.

20 (\*) Contributed equally, both authors act as first authors.

21 (&) Both authors act as senior authors.

22 (##) Members of the VAHNSI network listed at the end of the manuscript.

23 **# Corresponding author: F. Xavier López-Labrador. F.Xavier.Lopez@uv.es**

24 **Corresponding author mailing address:** Virology Laboratory, Genomics & Health Area,  
25 FISABIO-Public Health. Avenida de Cataluña, 21. 46020 Valencia, Spain.

26

27

28

29

30

31

32

NOTE: This preprint reports new research that has not been certified by peer review and should not be used to guide clinical practice.

### 33 **Abstract**

34 On March 9 2020 the WHO Global Influenza Program (GIP) asked participant sites on the Global  
35 Influenza Hospital Surveillance Network (GIHSN) to contribute to data collection concerning  
36 severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). We re-analysed 5,833 viral RNA  
37 archived samples collected prospectively from hospital admissions for influenza-like illness (ILI)  
38 in the Valencia Region of Spain by the VAHNSI network (4 hospitals, catchment area population  
39 1,118,732) during the prepandemic 2018/2019 (n=4,010) and pandemic 2019/2020 (n=1,823)  
40 influenza seasons, for the presence of SARS-CoV-2. We did not find evidence for community-  
41 acquired SARS-CoV-2 infection in hospital admissions for ILI in our region before early March  
42 2020.

43

### 44 **Introduction**

45 The first case of coronavirus disease 2019 (COVID-19) due to severe acute respiratory syndrome  
46 coronavirus (SARS-CoV-2) was detected in Wuhan (Hubei province, China) at the end of 2019  
47 and the virus rapidly spread to other Chinese provinces and countries (1). As of 3 June 2020, the  
48 World Health Organization (WHO) had already reported the presence of SARS-CoV-2 in 54  
49 different European countries (2). In Spain, the first imported and locally acquired COVID-19 cases  
50 were detected on 31 January, and 26 February 2020, respectively (3, 4). Since then, until  
51 beginning of June, Spain accounted for 240,660 confirmed cases and 27,133 deaths. Among total  
52 registered deaths, 86% were in people aged 70 or older and 95% had previous underlying chronic  
53 conditions (5). Symptomatology described by SARS-CoV-2-infected patients was almost identical  
54 to the common influenza-like illness (ILI) symptoms (6, 7), and COVID-19 cases may have  
55 occurred in Spain earlier than previously recognized (8). Besides, there is no data available on  
56 potential SARS-CoV-2 circulation during the prepandemic 2018/2019 influenza season.

57

### 58 **Methods**

59 Every influenza season, from November to March/April, the Valencia Hospital Surveillance  
60 Network for the Study of Influenza and Other Respiratory Viruses (VAHNSI) network conducts a  
61 prospective active-surveillance study on respiratory viral infections in 4 hospitals, providing  
62 healthcare to 1,118,732 (22% of total) inhabitants from the Valencia Region of Spain (Figure 1).  
63 Our network is integrated in the Global Influenza Hospital Surveillance Network (GIHSN) sharing  
64 data with the WHO GIP ([www.gihnsn.org/](http://www.gihnsn.org/)). Full-time dedicated nurses screen all hospitalized  
65 patients discharged from the Emergency Department if they referred a complain possibly  
66 related to a respiratory infection. Patients are included in the study if they are resident in the  
67 catchment area of one of the participating hospitals, non-institutionalised and not discharged

68 from a previous admission in the last 30 days. Patients have to meet the ECDC influenza-like  
69 illness (ILI) case definition (9), defined as the presence of, at least, one systemic symptom (fever  
70 or feverishness, malaise, myalgia or headache) and, at least, one respiratory symptom  
71 (shortness of breath, sore throat or cough), with an onset of symptoms in the 7 days prior to  
72 admission. For children less than 5 years old, we only require an onset of one symptom (Table  
73 S1) in the 7 days prior to admission. Finally, patients need to be in hospital between 8 and 48  
74 hours to be enrolled and swabbed (combined nasopharyngeal and oropharyngeal in universal  
75 transport medium), after written informed consent. Clinical and demographic characteristics  
76 from patients were obtained by a face-to-face interview or by consulting medical records.

77

78 Samples are tested in one centralized laboratory (FISABIO-Public Health) by real-time reverse-  
79 transcription polymerase chain reaction (RT-PCR) for 19 different viruses (influenza  
80 A(H1N1)pdm09, A(H3N2), B/Victoria and B/Yamagata, Respiratory Syncytial Virus (RSV) A and B,  
81 metapneumovirus, parainfluenza 1-4, rhinovirus/enterovirus, adenovirus, bocavirus, and  
82 coronavirus 229E, HKU1, NL63 and OC43). First, all available samples from the 2019/2020 season  
83 were re-analysed individually to detect SARS-CoV-2. An in-house assay was rapidly developed in  
84 February 2020 based in the WHO-Charité and U.S. CDC assays, to detect the SARS-CoV-2 E-gene  
85 (10) in multiplex together with the human cellular control RNase-P to ensure reliability of sample  
86 collection and nucleic acid extraction before RT-PCR. Only samples with RNase-P Ct values <35  
87 were considered valid. The limit of detection of the assay was established to 35 copies using the  
88 SARS-CoV-2 E-gene as reference material either as an insert in a pCDNA plasmid (a gift from Luis  
89 Enjuanes, Coronavirus laboratory, CNB-CSIC, Madrid, Spain) or as encapsulated RNA (a gift from  
90 Charité Medical Center, Berlin, through the European Virus Archive program). Further, to  
91 investigate the possibility of SARS-CoV-2 infection earlier to fall-winter 2019 than previously  
92 recognized, we retrospectively tested in pools of 10 samples available archived viral RNAs from  
93 nasopharyngeal samples collected from 4,010 individuals admitted because of ILI during the  
94 2018/2019 influenza season. The Ethics Research Committee of the Dirección General de Salud  
95 Pública-Centro Superior de Investigación en Salud Pública (DGSP-CSISP) previously approved the  
96 protocol for the study of respiratory viruses in the VANSHI network.

97

## 98 **Results**

99 A total of 5,176 patients were recruited in the VAHNSI network between November 2019 and  
100 mid-March, 2020 and 1,843 were included after applying exclusion criteria; 1,291 of them were  
101 PCR-negative for the 19 tested seasonal viruses and the remainder 552 had at least one  
102 detectable virus. After re-testing 1,823 available samples for SARS-CoV-2, either positive or

103 negative for seasonal viruses, only one SARS-CoV-2 positive was detected. The result was  
104 replicated in an independent sample at the hospital laboratory. Whole-genome sequencing was  
105 performed by metagenomic sequencing with spiked primer enrichment, MSSPE (11), using a  
106 primer set described by Manning *et al.* (<https://www.protocols.io/view/sars-cov-2-enrichment-sequencing-by-spiked-primer-bc36iyre>), and showed three amino acid changes from the hCoV-  
107 19/Wuhan/WIV04/2019 strain (P323L in NSP12, L117M in NSP8, and D614G in the S protein),  
108 belonging to GISAID G clade and PANGOLIN B.1.5 lineage. The infected patient was a man in his  
109 late 70's who was admitted to hospital on early March 2020 (epidemiological week 11/2020) for  
110 acute respiratory infection with fever, cough and malaise, with symptom onset 2 days prior to  
111 admission. Co-morbidities included diabetes and a prostate adenocarcinoma, but not obesity or  
112 smoking history. During hospitalization, he was not admitted in the Intensive Care Unit (ICU) nor  
113 required mechanical ventilation or extracorporeal membrane oxygenation (ECMO). However,  
114 the patient died five days after admission. As main discharge diagnosis, the ICD10-CM code J06.9  
115 was registered (acute upper respiratory tract infection, unspecified). Finally, all RNA pools from  
116 the 4,010 archived samples belonging to the prepandemic 2018/19 influenza season (back to  
117 September 2018) were SARS-CoV-2 RT-PCR negative.  
118

119

## 120 **Discussion**

121 To our knowledge, our study is the first comprehensive screening for SARS-CoV-2 in ILI cases at  
122 the population level in the prepandemic period in Europe. We describe here the first SARS-  
123 CoV-2 admission in the Valencia Region without travel history and thus likely due to  
124 community transmission in early March, 2020. The infected patient was an old diabetic man in  
125 his late 70's who was also developing a neoplasia. It is widely known that COVID19 mainly  
126 affects elderly people (12, 13) as well as people with underlying chronic conditions (14)  
127 including diabetes in an important percentage of severe cases (15, 16). Our patient had a weak  
128 health status. Apart from his chronic conditions, he had other frailty indicators (data available  
129 upon request). Although the patient was not admitted in the ICU, he finally died 5 days after  
130 admission.  
131

132

133 The first COVID19 cases in Spain were imported cases detected on 31 January 2020 in a  
134 German tourist in La Gomera, Canary Islands and in continental Spain on February 26, in an  
135 Italian returning from Milan (3, 4). In the Valencia Region of Spain, the first identified case was  
136 also imported (travel history to Nepal in late December 2019), detected in early February 2020  
137 in a Hospital not covered by our surveillance network (17). Excess cases of influenza detected  
by analysis of primary care electronic medical records suggested an earlier circulation of SARS-

138 CoV-2 in other regions of Spain (8), but no laboratory identification of SARS-CoV-2 was  
139 attempted. Retrospective identification of SARS-CoV-2 was also recently suggested in swabs  
140 collected for other diagnoses or in hospitalised cases with pneumonia in Spain, so the  
141 epidemic may have gone unnoticed prior to first case of local transmission (18). Unfortunately,  
142 laboratory data on that observation are yet unpublished.

143

144 Countries from the Northern Hemisphere were already engaged in seasonal influenza control  
145 when the SARS-CoV-2 outbreak started in China. Therefore, influenza surveillance systems  
146 with wide screening windows are perfect tools to retrospectively analyse the presence of the  
147 new SARS-CoV-2, because COVID19 shares most of the ILI symptomatology such as fever and  
148 cough (12). The first study based in retrospective analysis of samples from ILI cases was  
149 performed in Wuhan, China (October 2019-January 2020), detecting the first SARS-CoV-2 cases  
150 in the first week of January 2020, concomitant with significantly higher ILI cases for the 2019–  
151 2020 winter in comparison to previous years (19). In contrast, in our network of 4 tertiary-care  
152 hospitals in South-eastern Spain (covering a population of more than 1 million), the time of the  
153 first non-travel related SARS-CoV-2 hospital admission we detect is early March 2020 and  
154 coincided with the end of the peak of influenza and other respiratory viruses (Fig. 2). In  
155 addition, ILI inpatient cases for the 2019–2020 winter were not significantly higher in  
156 comparison to previous years: average percentage inpatients with ILI were 30% in 2019-20 in  
157 our catchment area, as compared to 36% during 2018-19, with no increased ILI cases during  
158 the first 10 epidemiological weeks. Phylodynamic analyses estimated the origin of SARS-CoV-2  
159 clusters in Spain around mid-February 2020 (21), which probably later completely replaced  
160 circulating seasonal respiratory viruses quickly in our region (Figure 2). In line with our results,  
161 SARS-CoV-2 was not detected in similar retrospective studies on inpatients limited to few cases  
162 in another region of Spain (n=170; 1 January - 25 February 2020) (20), central Italy (n=166; 1  
163 November 2019 - 1 March 2020) (22), or in only 2/2,888 inpatients and outpatients who had  
164 negative results by routine respiratory virus testing in the United States between 1 January  
165 2020 - 26 February 2020 (23). Collectively, our results and published data indicate that the  
166 early pandemic phase was still dominated by seasonal respiratory viruses, with very low  
167 circulation of SARS-CoV-2 in the community and probably a limited period of overlap with  
168 influenza circulation (24-25). Whether pre-existing immune memory and innate immune  
169 interference shaped SARS-CoV-2 spread deserves further investigation (24).

170

171 The first SARS-CoV-2 cases in hospital admissions in Europe had been identified at the end of  
172 January or early February 2020 as related to travel to, or to contacts with, travellers from China

173 (26-28). Later, retrospective analysis identified earlier cases from early or late December 2019  
174 in Italy and France, respectively (29, 30). Some studies have suggested circulation of SARS-CoV-  
175 2 may have occurred even earlier than December 2019. A retrospective study on blood samples  
176 from Italy found SARS-CoV-2 receptor-binding domain (RBD) specific antibodies as early as  
177 September 2019 (30) but whether this observation is due to cross-reactivity with common cold  
178 coronaviruses or true SARS-CoV-2 infection is unknown. Previous retrospective sample studies  
179 based on RT-PCR testing are limited to 2020 or late December 2019 (22-24, 29, 30). In contrast,  
180 we analyzed ILI samples back to September 2018, and found no evidence supporting SARS-CoV-  
181 2 circulation in hospitalized community-acquired ILI during the prepandemic 2018/2019 or  
182 pandemic 2019/2020 influenza seasons, prior to early March 2020.

183

184 Our study has several limitations. First, the VAHNSI network was designed for detecting  
185 influenza cases, therefore COVID19 cases presenting a symptomatology different from  
186 influenza were not detected. Second, the pandemic disruption situation forced the  
187 interruption of hospital surveillance activities in mid-March, just after the declaration of the  
188 state of alarm by the Spanish Government. More cases of SARS-CoV-2 would have been  
189 detected should the study had not been stopped. Finally, it is possible that pooled testing for  
190 2018-19 samples led to lower RT-PCR sensitivity. However, pool sizes of up to 10 samples have  
191 been proven to maintain high performance when compared with individual sample testing (23,  
192 32).

193

194 Despite these limitations, here we show how influenza surveillance networks are a powerful  
195 resource to analyse the presence of the new respiratory viruses sharing the ILI / SARI  
196 symptomatology, because routine collection and storage of samples months (and eventually  
197 years) before the occurrence of a new virus introduction. Using these networks will allow us to  
198 expand surveillance of SARS-CoV-2, to detect unexpected pathogens in the future, and to  
199 elaborate a better map and seasonality for SARS-CoV-2 circulation during the next influenza  
200 season. The transition of influenza surveillance networks to other respiratory viruses is thus  
201 warranted.

202

### 203 **Acknowledgements.**

204 FXLL and BMC is supported by the CIBEResp, Instituto de Salud Carlos III, Spain. Data collection  
205 was partially supported by a grant from the Foundation for Influenza Epidemiology (FIE), which  
206 supports the Global Influenza Hospital Surveillance Network (see [www.gihsn.org](http://www.gihsn.org) for more  
207 details). The sponsor did not participate in the study design, data analysis and interpretation,

208 in the writing of the manuscript or in the decision to submit the manuscript for publishing. The  
209 authors thank the staff of Hospital General de Castellón, in Castellón; Hospital La Fe, in  
210 Valencia; Hospital Doctor Peset, in Valencia; Hospital General de Alicante, in Alicante for their  
211 support and contribution to the Valencia Hospital Network for the Study of Influenza and  
212 Respiratory Viruses Disease (VAHNSI) network.  
213

214 **References**

- 215 1. WHO. Novel Coronavirus (2019-nCoV). Situation report - 1. 21 January 2020: World Health  
216 Organization; 2020 [Available from: [https://www.who.int/docs/default-](https://www.who.int/docs/default-source/coronaviruse/situation-reports/20200121-sitrep-1-2019-ncov.pdf?sfvrsn=20a99c10_4)  
217 [source/coronaviruse/situation-reports/20200121-sitrep-1-2019-ncov.pdf?sfvrsn=20a99c10\\_4](https://www.who.int/docs/default-source/coronaviruse/situation-reports/20200121-sitrep-1-2019-ncov.pdf?sfvrsn=20a99c10_4).
- 218 2. WHO. Coronavirus disease (COVID-19) Situation Report-135: World Health Organization;  
219 2020 [Available from: [https://www.who.int/docs/default-source/coronaviruse/situation-](https://www.who.int/docs/default-source/coronaviruse/situation-reports/20200603-covid-19-sitrep-135.pdf?sfvrsn=39972feb_2)  
220 [reports/20200603-covid-19-sitrep-135.pdf?sfvrsn=39972feb\\_2](https://www.who.int/docs/default-source/coronaviruse/situation-reports/20200603-covid-19-sitrep-135.pdf?sfvrsn=39972feb_2).
- 221 3. Centro Nacional de Epidemiología, Instituto de Salud Carlos III (ISCIII). Primeros casos  
222 investigados en España por Covid-2019. Informe Covid-2019 no 1. [First Covid-19 cases in  
223 Spain. Covid-2019 report no 1]. Madrid: ISCIII; 2020. Spanish. Available from:  
224 [https://www.isciii.es/QueHacemos/Servicios/VigilanciaSaludPublicaRENAVE/EnfermedadesTra-](https://www.isciii.es/QueHacemos/Servicios/VigilanciaSaludPublicaRENAVE/EnfermedadesTransmisibles/Documents/INFORMES/Informes%20COVID-19/Informe%20COVID-19.%20N%c2%ba%201_11febrero2020_ISCIII.pdf)  
225 [nsmisibles/Documents/INFORMES/Informes%20COVID-19/Informe%20COVID-](https://www.isciii.es/QueHacemos/Servicios/VigilanciaSaludPublicaRENAVE/EnfermedadesTransmisibles/Documents/INFORMES/Informes%20COVID-19/Informe%20COVID-19.%20N%c2%ba%201_11febrero2020_ISCIII.pdf)  
226 [19.%20N%c2%ba%201\\_11febrero2020\\_ISCIII.pdf](https://www.isciii.es/QueHacemos/Servicios/VigilanciaSaludPublicaRENAVE/EnfermedadesTransmisibles/Documents/INFORMES/Informes%20COVID-19/Informe%20COVID-19.%20N%c2%ba%201_11febrero2020_ISCIII.pdf)
- 227 4. Instituto de Salud Carlos III (ISCIII). Informe sobre los casos de COVID-19 confirmados en  
228 España Informe COVID-19 no 3. [Report on confirmed COVID-19 cases in Spain. COVID-19  
229 report no 3]. Madrid: ISCIII; 2020. Spanish. Available from:  
230 [https://www.isciii.es/QueHacemos/Servicios/VigilanciaSaludPublicaRENAVE/EnfermedadesTra-](https://www.isciii.es/QueHacemos/Servicios/VigilanciaSaludPublicaRENAVE/EnfermedadesTransmisibles/Documents/INFORMES/Informes%20COVID-19/Informe%20COVID-19.%20N%c2%ba%203_28febrero2020_ISCIII.pdf)  
231 [nsmisibles/Documents/INFORMES/Informes%20COVID-19/Informe%20COVID-](https://www.isciii.es/QueHacemos/Servicios/VigilanciaSaludPublicaRENAVE/EnfermedadesTransmisibles/Documents/INFORMES/Informes%20COVID-19/Informe%20COVID-19.%20N%c2%ba%203_28febrero2020_ISCIII.pdf)  
232 [19.%20N%c2%ba%203\\_28febrero2020\\_ISCIII.pdf](https://www.isciii.es/QueHacemos/Servicios/VigilanciaSaludPublicaRENAVE/EnfermedadesTransmisibles/Documents/INFORMES/Informes%20COVID-19/Informe%20COVID-19.%20N%c2%ba%203_28febrero2020_ISCIII.pdf)
- 233 5. Ministerio de Sanidad. Actualización nº 126. Enfermedad por el coronavirus (COVID-19)  
234 04.06.2020: Ministerio de Sanidad. Gobierno de España.; 2020 [Available from:  
235 [https://www.mscbs.gob.es/profesionales/saludPublica/ccayes/alertasActual/nCov-](https://www.mscbs.gob.es/profesionales/saludPublica/ccayes/alertasActual/nCov-China/documentos/Actualizacion_126_COVID-19.pdf)  
236 [China/documentos/Actualizacion\\_126\\_COVID-19.pdf](https://www.mscbs.gob.es/profesionales/saludPublica/ccayes/alertasActual/nCov-China/documentos/Actualizacion_126_COVID-19.pdf).
- 237 6. Huang C, Wang Y, Li X, Ren L, Zhao J, Hu Y, et al. Clinical features of patients infected with  
238 2019 novel coronavirus in Wuhan, China. *Lancet*. 2020;395(10223):497-506.
- 239 7. Wang L, He WB, Yu XM, Hur DL, Bao MW, Liu HF, et al. Coronavirus disease 2019 in elderly  
240 patients: Characteristics and prognostic factors based on 4-week follow-up. *Journal of*  
241 *Infection*. 2020;80(6):639-45.
- 242 8. Coma E, Mora N, Prats-Urbe A, Fina F, Prieto-Alhambra D, Medina-Peralta M. Excess cases  
243 of influenza suggest an earlier start to the coronavirus epidemic in Spain than official figures  
244 tell us: an analysis of primary care electronic medical records from over 6 million people from



- 245 Catalonia. medRxiv 2020:2020.2004.2009.20056259. Available from:  
246 <http://dx.doi.org/2020.04.09.20056259>
- 247 9. European Commission. Commission Implementing Decision of 8 August 2012 amending  
248 Decision 2002/253/EC laying down case definitions for reporting communicable diseases to the  
249 Community network under Decision No. 2119/98/EC of the European Parliament and of the  
250 Council (notified under document C(2012) 5538). European Commission. Luxembourg:  
251 Publications Office of the European Union; 2012 [Available from: [https://eur-](https://eur-lex.europa.eu/legal-content/EN/TXT/PDF/?uri=CELEX:32012D0506&qid=1428573336660&from=EN#page=16)  
252 [lex.europa.eu/legal-](https://eur-lex.europa.eu/legal-content/EN/TXT/PDF/?uri=CELEX:32012D0506&qid=1428573336660&from=EN#page=16)  
253 [content/EN/TXT/PDF/?uri=CELEX:32012D0506&qid=1428573336660&from=EN#page=16](https://eur-lex.europa.eu/legal-content/EN/TXT/PDF/?uri=CELEX:32012D0506&qid=1428573336660&from=EN#page=16)].
- 254 10. WHO. Molecular assays to diagnose COVID-19: Summary table of available protocols. 24  
255 January 2020. [https://www.who.int/publications/m/item/molecular-assays-to-diagnose-covid-](https://www.who.int/publications/m/item/molecular-assays-to-diagnose-covid-19-summary-table-of-available-protocols)  
256 [19-summary-table-of-available-protocols](https://www.who.int/publications/m/item/molecular-assays-to-diagnose-covid-19-summary-table-of-available-protocols)
- 257 11. Deng X, Achari A, Federman S, Yu G, Somasekar S, Bártolo I, et al. Metagenomic sequencing  
258 with spiked primer enrichment for viral diagnostics and genomic surveillance. *Nat Microbiol.*  
259 2020 Mar;5(3):443-454.
- 260 12. Guan W, Ni Z, Hu Y, Liang W, Ou C, He J, et al. Clinical Characteristics of Coronavirus  
261 Disease 2019 in China. *New England Journal of Medicine.* 2020;382(18):1708-20.
- 262 13. Liu K, Chen Y, Lin R, Han K. Clinical features of COVID-19 in elderly patients: A comparison  
263 with young and middle-aged patients. *Journal of Infection.* 2020;80(6):E14-E8.
- 264 14. Liu H, Chen S, Liu M, Nie H, Lu H. Comorbid Chronic Diseases are Strongly Correlated with  
265 Disease Severity among COVID-19 Patients: A Systematic Review and Meta-Analysis. *Aging and*  
266 *Disease.* 2020;11(3):668-78.
- 267 15. Wu J, Zhang J, Sun X, Wang L, Xu Y, Zhang Y, et al. Influence of diabetes mellitus on the  
268 severity and fatality of SARS-CoV-2 infection. *Diabetes, obesity & metabolism.* 2020.
- 269 16. Shi M, Chen L, Yang Y, Zhang J, Xu J, Xu G, et al. Analysis of clinical features and outcomes  
270 of 161 patients with severe and critical COVID-19: A multicenter descriptive study. *Journal of*  
271 *clinical laboratory analysis.* 2020:e23415.
- 272 17. Navarro Conde P, Alemany Monraval P, Medina Medina C, Jiménez Sánchez A, Andrés  
273 Teruel JC, Ferrando Marco J, et al. Autopsy findings from the first known death from Severe  
274 Acute Respiratory Syndrome SARS-CoV-2 in Spain. *Revista Española de Patología*  
275 2020;53(3):188-192.

- 276 18. Working group for the surveillance and control of COVID-19 in Spain. The first wave of the  
277 COVID-19 pandemic in Spain: characterisation of cases and risk factors for severe outcomes, as  
278 at 27 April 2020. *Eurosurveillance*, 25, 2001431 (2020), [https://doi.org/10.2807/1560-](https://doi.org/10.2807/1560-7917.ES.2020.25.50.2001431)  
279 7917.ES.2020.25.50.2001431
- 280 19. Kong W-H, Li Y, Peng M-W, Kong D-G, Yang X-B, Wang L, et al. SARS-CoV-2 detection in  
281 patients with influenza-like illness. *Nature Microbiology* 2020;5(5):675-678.  
282 <https://doi.org/10.1038/s41564-020-0713-1>
- 283 20. Diez-Fuertes F, Iglesias-Caballero M, García-Pérez J, Monzón S, Jiménez P, Varona S, et al. A  
284 Founder Effect Led Early SARS-CoV-2 Transmission in Spain. *Journal of Virology*  
285 2021;95(3):e01583-01520.
- 286 21. Blanco-Suarez A, Pérez-Jové P, Escribano-Castillejo N, Ballester-Tellez M. Retrospective  
287 search of SARS-CoV-2 in respiratory samples in Vallès Occidental (Barcelona, Spain) before the  
288 first case was reported. *Enfermedades Infecciosas y Microbiología Clínica* 2020;38(10):511-  
289 512.
- 290 22. Capalbo C, Bertamino E, Zerbetto A, Santino I, Petrucca A, Mancini R, et al. No Evidence of  
291 SARS-CoV-2 Circulation in Rome (Italy) during the Pre-Pandemic Period: Results of a  
292 Retrospective Surveillance. *International Journal of Environmental Research and Public Health*  
293 2020;17(22).
- 294 23. Hogan C, Garamani N, Sahoo M, Huang C, Zehnder J, Pinsky B. Retrospective Screening for  
295 SARS-CoV-2 RNA in California, USA, Late 2019. *Emerging Infectious Disease journal*  
296 2020;26(10):2487. PMID: 32620178 PMCID: PMC7510744 DOI: 10.3201/eid2610.202296
- 297 24. Leuzinger K, Roloff T, Gosert R, Sogaard K, Naegele K, Rentsch K, et al. Epidemiology of  
298 Severe Acute Respiratory Syndrome Coronavirus 2 Emergence Amidst Community-Acquired  
299 Respiratory Viruses. *The Journal of Infectious Diseases* 2020 1/8/2021;222(8):1270-1279.
- 300 25. Stowe J, Tessier E, Zhao H, Guy R, Muller-Pebody B, Zambon M, et al. Interactions between  
301 SARS-CoV-2 and Influenza and the impact of coinfection on disease severity: A test negative  
302 design. *MedRxiv* 2020:2020.09.18.20189647. <https://doi.org/10.1101/2020.09.18.20189647>.
- 303 26. Olsen SJ, Meng-Yu C, Yu-Lun L, Mark W, Alexis A, Clementine C, et al. Early Introduction of  
304 Severe Acute Respiratory Syndrome Coronavirus 2 into Europe. *Emerging Infectious Disease*  
305 *journal* 2020;26(7).

- 306 27. Lescure F-X, Bouadma L, Nguyen D, Parisey M, Wicky P-H, Behillil S, et al. Clinical and  
307 virological data of the first cases of COVID-19 in Europe: a case series. *The Lancet Infectious*  
308 *Diseases* 2020;20(6):697-706.
- 309 28. Spiteri G, Fielding J, Diercke M, Campese C, Enouf V, Gaymard A, et al. First cases of  
310 coronavirus disease 2019 (COVID-19) in the WHO European Region, 24 January to 21 February  
311 2020. *2020*;25(9):2000178.
- 312 29. Amendola A, Bianchi S, Gori M, Colzani D, Canuti M, Borghi E, et al. Evidence of SARS-CoV-2  
313 RNA in an Oropharyngeal Swab Specimen, Milan, Italy, Early December 2019. *Emerging*  
314 *Infectious Disease journal* 2020;27(2).
- 315 30. Deslandes A, Berti V, Tandjaoui-Lambotte Y, Alloui C, Carbonnelle E, Zahar JR, et al. SARS-  
316 CoV-2 was already spreading in France in late December 2019. *International Journal of*  
317 *Antimicrobial Agents* 2020;55(6):106006.
- 318 31. Apolone G, Montomoli E, Manenti A, Boeri M, Sabia F, Hyseni I, et al. Unexpected  
319 detection of SARS-CoV-2 antibodies in the prepandemic period in Italy. *Tumori Journal* 2020  
320 2020/11/17:0300891620974755.
- 321 32. Hogan CA, Sahoo MK, Pinsky BA. Sample Pooling as a Strategy to Detect Community  
322 Transmission of SARS-CoV-2. *JAMA*; 2020. p. 1967-1969. PMID: 32250394 PMCID:  
323 PMC7136853 DOI: 10.1001/jama.2020.5445.

324




325

326 **Figure 1.** Map of the covered population area in south-east Spain (red). The number of  
327 inhabitants covered by the VAHNSI network is 1,118,732.

328

329



330

331 **Figure 2.** Number of detections for 19 respiratory viruses in the VAHNSI network during the  
332 2019/20 influenza season by epidemiological week (November 1<sup>st</sup> 2019 to March 14<sup>th</sup> 2020).  
333 The timing for the first ILI admission positive for SARS-CoV-2 is indicated.

334